Bermudez Christian A, Shiose Akira, Esper Stephen A, Shigemura Norihisa, D'Cunha Jonathan, Bhama Jay K, Richards Thomas J, Arlia Peter, Crespo Maria M, Pilewski Joseph M
Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Ann Thorac Surg. 2014 Dec;98(6):1936-42; discussion 1942-3. doi: 10.1016/j.athoracsur.2014.06.072. Epub 2014 Oct 22.
The intraoperative use of cardiopulmonary bypass (CPB) in lung transplantation has been associated with increased rates of pulmonary dysfunction and bleeding complications. More recently, extracorporeal membrane oxygenation (ECMO) has emerged as a valid alternative method of support and has been our preferred method of support since March 2012. We compared early and midterm outcomes of these 2 support methods.
Between July 2007 and April 2013, 271 consecutive patients underwent lung transplant using CPB (n = 222) or ECMO (n = 49). We retrospectively reviewed the outcomes of these patients requiring CPB or ECMO during lung transplant.
The CPB and ECMO groups had comparable demographic and operative characteristics; however, the ECMO group had higher mean lung allocation scores (73 vs 52, p < 0.001). In the CPB group, more patients required reintubation (35.6% vs 20.4%, p = 0.04) or temporary tracheostomy (44.6% vs 28.6%, p = 0.05). Patients in the CPB group had a higher rate of renal failure requiring dialysis than the ECMO group (22.1% vs 8.2 %, p = 0.028). There were no differences in severe PGD requiring postoperative circulatory support (p = 0.83) or the need for perioperative red blood cell transfusions (p = 0.64) between the groups. No differences in 30-day (5% CPB vs 4.1% ECMO) or 6-month mortality (14.4% CPB vs 14.3% ECMO) were noted.
The use of ECMO in lung transplant is safe and in our experience was associated with decreased rates of pulmonary and renal complications, as compared with CPB. Extracorporeal membrane oxygenation has become our preferred method of intraoperative support during lung transplantation.
肺移植术中使用体外循环(CPB)与肺功能障碍和出血并发症发生率增加相关。最近,体外膜肺氧合(ECMO)已成为一种有效的替代支持方法,自2012年3月以来一直是我们首选的支持方法。我们比较了这两种支持方法的早期和中期结果。
2007年7月至2013年4月期间,271例连续患者接受了使用CPB(n = 222)或ECMO(n = 49)的肺移植。我们回顾性分析了这些在肺移植期间需要CPB或ECMO的患者的结果。
CPB组和ECMO组在人口统计学和手术特征方面具有可比性;然而,ECMO组的平均肺分配评分更高(73对52,p < 0.001)。在CPB组中,更多患者需要再次插管(35.6%对20.4%,p = 0.04)或临时气管切开术(44.6%对28.6%,p = 0.05)。CPB组患者需要透析的肾衰竭发生率高于ECMO组(22.1%对8.2%,p = 0.028)。两组之间在需要术后循环支持的严重原发性移植肺失功(p = 0.83)或围手术期红细胞输血需求(p = 0.64)方面没有差异。30天死亡率(CPB组为5%,ECMO组为4.1%)或6个月死亡率(CPB组为14.4%,ECMO组为14.3%)没有差异。
在肺移植中使用ECMO是安全的,根据我们的经验,与CPB相比,其肺和肾并发症发生率较低。体外膜肺氧合已成为我们肺移植术中首选的支持方法。